“Junko Saber and I started Innopiphany with the goal of creating a unique service-oriented consulting group that would give our customers greater flexibility and superb insights quickly. Each of us has been working in life sciences since 1994 with 14 years related consulting experience. Our goal is to give you, our future customer, excellence and acumen in everything we deliver to make your journey with us effortless.”

– Lisa Kennedy, Founder

Lisa Kennedy

Managing Principal

Dr. Lisa Kennedy specializes in strategy, new business model innovation, marketing, market access, macroeconomic health analysis and commercialization. Dr. Kennedy was GM for the Lewin Group Europe and in 2005, Dr. Kennedy joined GE Healthcare as Chief Economist where she received the CEO’s President Award in this role. She has also held roles as Global Head of Marketing Operations for GE Healthcare’s 1500-strong marketing organization, where she managed the innovation portfolio of over 200 products and services; and led GE Healthcare’s strategy (Growth Playbook) during which the company grew $2B. In 2009 she was awarded the GE Vice Chairman’s Award from John Rice.

As Chief Marketing Officer for healthymagination, she led innovation including consumer health incubation and strategic marketing including all branding efforts. Under her leadership, Dr. Kennedy and her team have been recognized with awards from the UN, the White House, IDEA, the Triple Negative Foundation and the National Association of Female Executives. She was a curator for TEDMED’s 2013 Start-Up HIVE, a mentor for Rock Health and is Adjunct Faculty for Singularity University. Dr. Kennedy has several peer-reviewed articles, including an editorial for the British Journal of Cardiology.

She has spoken over 100 times internationally on healthcare open innovation, crowdsourcing, disruptive growth, affordability, eHealth, health policy, ambient intelligence and quantified self, including for NASA, the NHS, the EU, SXSW, FutureMed and the White House Office of Science and Technology Policy (OSTP), most recently keynoting for HIMSS. The Wall Street Journal and National Public Radio have quoted Dr. Kennedy on future healthcare trends in consumer health. At the age of 25, she received the 1994 Russel Trust Award and the Gray Prize for research supported by Sir John Crofton that changed WHO practice in the treatment of tuberculosis in Addis Ababa, Ethiopia.

Junko Saber

Managing Principal

Junko Saber has over 20 years of life sciences experience, with the past 10 years in life sciences management consulting. She is an expert in Excel modeling, market forecasting, marketing strategy and core messaging. She has expertise in conducting global qualitative research and in moderating advisory boards. Junko’s experience ranges across a variety of therapeutic areas, including, but not limited to endocrinology, cardiology, oncology, and CNS and HCV. Prior to consulting, Junko spent a decade working in industry at Merck, Genzyme and Abbott Laboratories, where she held various positions in project management, clinical development, resource and research planning and regulatory affairs. Junko holds an MBA from New York University and a Bachelor Degrees in Chemistry and Japanese from the University of California at Berkeley.

Robin Thompson


Robin Thompson is a health economist with 25 years of industry, academic, and international health development experience.  He has a PhD in Economics from the University of York, UK and has expertise in market access strategy, value-demonstration, value-based pricing, health technology assessment and real-world evidence.  He has considerable experience of regulatory/payor engagement, including supporting EMA/HTA parallel advice and coordinating ICER and global HTA interactions.  Robin has worked across a diverse range of therapeutic areas, including, but not limited to, oncology, cardiology, ophthalmology and more recently, rare diseases and Alzheimer’s disease. He was worked in roles of increasing seniority and leadership for Pfizer, Eli Lily and Biogen at affiliate, regional and global levels

Mahmoud Loghman-Adham

Chief Medical Officer

Mahmoud Loghman-Adham, MD is a pediatric nephrologist by training, currently a consultant to pharmaceutical and biotech industry. Most recently, he was a Medical Director at Baxalta (now part of Shire), in Westlake Village, California. He provides strategic medical and scientific advice on clinical trial design and execution and on business development, including due diligence for new molecules to treat orphan diseases. Prior to joining Baxalta, he was a Senior Medical Director and a Translational Medicine Leader at Hoffmann-La Roche Inc, starting in 2001. He has led clinical trials from Phase 2 to 4 in anemia, renal diseases, inflammatory and autoimmune diseases, emphysema/COPD, and hematology /oncology. He has worked on biomarker identification and selection and their incorporation into proof-of-concept clinical trials. His areas of interest include chronic kidney disease, nephrotoxicity, inflammatory/auto-immune diseases and pulmonary diseases.

Deanna Darlington


Deanna Darlington is an Advocacy Relations Professional with more than 25 years of experience in government and external affairs, patient advocacy, policy, reimbursement consulting, and other related fields. She specializes in engaging patient advocacy organizations on access and policy issues which includes a focus on health disparities for vulnerable patient populations. Deanna works closely with advocates on key policy issues that support dialogue and engagement to patient access to quality care and value. For 13 years, Deanna held various roles at Amgen Inc., that included policy and patient advocacy/alliance development. Deanna also served as Director of Reimbursement and Policy at a number of other Pharma companies. Before joining the biotech and biopharmaceutical industry, she served as the first Reimbursement Specialist for the American Society of Clinical Oncology where she staffed the Clinical Practice Committee and developed the State Affiliate Program under the Association’s Public Policy arm.

Lakshmi Sundar


Lakshmi is an intrapreneur and innately curious change agent passionate about transforming businesses and the lives of the customers they serve. In her 20 plus year career in the life sciences space, Lakshmi has served in leadership roles across the Marketing, Strategy, Technology, and Communications functions to help companies to break through fundamental market changes, get out of stasis, and scale for significant growth. Lakshmi’s strength in analyzing and breaking down complex problems, working with teams to craft and implement winning solutions, and communicating value propositions with gusto has helped her bring about change in both public and privately held companies that resulted in significant business growth/market leadership and reach across a variety of target audiences. An early adopter of social media, Lakshmi has developed social media strategies for effective outreach, knowledge sharing, community building, and experience collating for audiences ranging from clinicians, clinical trial professionals, patients, radiology/cardiology technicians, radiologists, cardiologists, oncologists, and more. Additionally, Lakshmi has harnessed the power of webinars, online forums, conferences, and communities to bring the most current thinking to her target audiences, propelled them to discuss solutions to long-standing problems, and encouraged them to be active collaborators and problem-solvers to bring about much-needed change. In addition to her significant accomplishments as a business leader, Lakshmi is also a published author, a TEDx speaker, an avid enthusiast/communicator on social media on food/travel, and a coach/mentor to youth/adults navigating change.

Susan Haynie


Dr. Susan Haynie is a Data Scientist and Applied Demographer specializing in custom geospatial, demographic and data analytics services. She creates unique research approaches by incorporating cross-industry experience and advanced skills in Alteryx (a leading data science, big data and machine learning platform). She has demonstrated success working in multiple industries including healthcare, retail, utilities, and entertainment. She is an expert in business information evaluation and acquisition, data cleansing, formatting of large unstructured datasets to reveal new information, and statistical and mathematical modeling. Highlights of her work include identifying high-priority, at-risk consumers by analyzing sales data for a major medical organization; estimating health care and insurance-potential models for the elderly population based on geo-demographics and survey response patterns; developing models of age-specific fertility / mortality rates for China accounting for variations in the one-child policy and migrant population flows by region; and, following the 2008 Sichuan, China earthquake, calculating affected population counts and locating health facilities by varying levels of earthquake intensity, improving response time and resource mobilization for life-saving relief organizations including the IFRC. Dr. Haynie was awarded a National Institute of Health SBIR (Small Business Innovation Research) grant –- “Small Area Demographic Estimates for China with Remote Sensing, GIS and Spatial Modeling.” She is a published author and has presented at conferences in the USA and China. She received her Ph.D. in Sociology (Demography and Advanced Quantitative Methods) from the University of Southern California, and was awarded the 2018 Alteryx Designer Advanced Certification.

Martin Zagari


Dr. Martin Zagari – Principal, Innopiphany is the former Vice President of Global Health Economics at Amgen. In this role, he directed the planning, execution and scientific dissemination of worldwide economic and value evidence for Amgen’s entire product portfolio from early stage molecules to marketed products. Prior to Amgen, Dr. Zagari held various positions at Johnson & Johnson in Health Economics, Medical Affairs, and Strategic Marketing. These positions included: Executive Director in J&J Corporate Strategic Marketing for the erythropoietic agents, Medical Director for erythropoietic treatments in oncology at Ortho Biotech, and Director positions in Health Economics. Prior to that, Dr. Zagari worked in Health Economics and Outcomes consulting at Technology Assessment Group/Lewin-TAG, based in San Francisco. Martin received his MD from Stanford University, an MBA from Rutgers University, and BS in Biology from the University of North Carolina at Chapel Hill and is trained in anesthesiology. He is currently also pursuing his Master of Engineering in Artificial Intelligence at University of San Diego.

Ernie Lee


Ernie Lee is a Consultant at Innopiphany, bringing a background in Market Access Strategy, Health Economics and Outcomes Research, and M&A strategy and due diligence. Ernie’s responsibilities include engaging in strategic market entry, product launch, HEOR engagements, and market access and reimbursement. Past work includes go-to market strategy, revenue modelling, and health economics modelling with a focus on U.S. and EU5 regions. He has experience across a broad range of therapeutic areas with a focus on rare diseases, oncology, and Alzheimer’s Disease. Ernie previously served as a Consultant at Certara in the US Access Strategy group supporting pharmaceutical companies in commercial strategy and investors in acquisition strategy and due diligence. Ernie began his career as an Analyst and Associate at Innopiphany. Outside of work, Ernie enjoys skiing and running at a moderate pace. Ernie holds a Bachelor of Science in Biochemistry from the University of California Los Angeles.

Kyra Lee

Senior Associate

Dr. Kyra Lee graduated from Caltech with a PhD in Chemistry in 2020 with a research background in bio-analytics and diagnostic device work. She specialized in semiconductor physics, 2-D materials, chemical synthesis, and data visualization/statistical techniques. She also held a scientific advising role at Quinn Emanuel Urquhart & Sullivan, LLP advising on various IP cases such as Caltech vs. Broadcom and Apple (error correction coding) which won a $1.1 billion dollar verdict in Jan 2020. She has experience in evaluating novel decision-making in HTA and outcomes, RWE, diagnostics and COVID-19 evidence and HTA. She also volunteered for the Federal Public Defender’s office in Los Angeles to advise as a science consult on various chemicals involved with methamphetamines to better equip the office on current/future drug cases. At the age of 22 she won the undergraduate researcher of the year in the 2012 American Chemical Society (ACS) Division of Analytical Chemistry.

Katarina Irwin


Katarina Irwin graduated the University of Southern California in 2017 with a Bachelor of Science in Mechanical Engineering and carried on to obtain her Masters of Science in Marketing Analytics at her alma mater. She is experienced in alternative payment models, stakeholder mapping, modeling, and crafting ICER response documents such as Value for Cures and the 2019 Sickle Cell Disease assessment. Katarina has expertise in health care analytics, data visualization, coding, forecasting & valuation, and market research for healthcare, engineering, and business applications for both clinical stage and commercial therapies. She has worked in several therapeutic and policy areas including population health analytics and companion diagnostics as well as therapeutic areas such as oncology, rare, and infectious disease. Prior to Innopiphany, Katarina worked as an analyst at finance/valuation and industrial corporations.